Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.40
BRKR's Cash to Debt is ranked higher than
65% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. BRKR: 1.40 )
BRKR' s 10-Year Cash to Debt Range
Min: 0.16   Max: 9999
Current: 1.4

0.16
9999
Equity to Asset 0.41
BRKR's Equity to Asset is ranked higher than
57% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. BRKR: 0.41 )
BRKR' s 10-Year Equity to Asset Range
Min: 0.15   Max: 0.68
Current: 0.41

0.15
0.68
Interest Coverage 7.92
BRKR's Interest Coverage is ranked higher than
53% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 178.70 vs. BRKR: 7.92 )
BRKR' s 10-Year Interest Coverage Range
Min: 0.71   Max: 9999.99
Current: 7.92

0.71
9999.99
F-Score: 5
Z-Score: 3.89
M-Score: -2.68
WACC vs ROIC
5.12%
8.45%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 5.83
BRKR's Operating margin (%) is ranked higher than
78% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.24 vs. BRKR: 5.83 )
BRKR' s 10-Year Operating margin (%) Range
Min: -3.71   Max: 13.34
Current: 5.83

-3.71
13.34
Net-margin (%) 3.13
BRKR's Net-margin (%) is ranked higher than
77% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.46 vs. BRKR: 3.13 )
BRKR' s 10-Year Net-margin (%) Range
Min: -6.73   Max: 9.58
Current: 3.13

-6.73
9.58
ROE (%) 6.81
BRKR's ROE (%) is ranked higher than
80% of the 272 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.91 vs. BRKR: 6.81 )
BRKR' s 10-Year ROE (%) Range
Min: -9.05   Max: 23.93
Current: 6.81

-9.05
23.93
ROA (%) 2.89
BRKR's ROA (%) is ranked higher than
80% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.48 vs. BRKR: 2.89 )
BRKR' s 10-Year ROA (%) Range
Min: -5.06   Max: 11.34
Current: 2.89

-5.06
11.34
ROC (Joel Greenblatt) (%) 16.91
BRKR's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.80 vs. BRKR: 16.91 )
BRKR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6.11   Max: 51.88
Current: 16.91

-6.11
51.88
Revenue Growth (3Y)(%) 2.50
BRKR's Revenue Growth (3Y)(%) is ranked higher than
66% of the 210 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. BRKR: 2.50 )
BRKR' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 22.8
Current: 2.5

0
22.8
EBITDA Growth (3Y)(%) -5.70
BRKR's EBITDA Growth (3Y)(%) is ranked higher than
68% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. BRKR: -5.70 )
BRKR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 153.7
Current: -5.7

0
153.7
EPS Growth (3Y)(%) -15.70
BRKR's EPS Growth (3Y)(%) is ranked higher than
66% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. BRKR: -15.70 )
BRKR' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 57.4
Current: -15.7

0
57.4
» BRKR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

BRKR Guru Trades in Q2 2014

Paul Tudor Jones 27,571 sh (New)
Louis Moore Bacon 190,000 sh (New)
Joel Greenblatt 898,448 sh (+845.99%)
Pioneer Investments 344,237 sh (+19.68%)
NWQ Managers 1,211,209 sh (+0.35%)
Vanguard Health Care Fund 3,285,758 sh (unchged)
Murray Stahl 32,993 sh (-2.86%)
Jim Simons 259,110 sh (-42.45%)
» More
Q3 2014

BRKR Guru Trades in Q3 2014

Joel Greenblatt 1,440,516 sh (+60.33%)
Murray Stahl 43,262 sh (+31.12%)
Paul Tudor Jones 32,794 sh (+18.94%)
NWQ Managers 1,312,031 sh (+8.32%)
Vanguard Health Care Fund 3,285,758 sh (unchged)
Pioneer Investments 387,897 sh (unchged)
Louis Moore Bacon Sold Out
Jim Simons 255,960 sh (-1.22%)
» More
Q4 2014

BRKR Guru Trades in Q4 2014

Paul Tudor Jones 132,100 sh (+302.82%)
Vanguard Health Care Fund 4,669,258 sh (+42.11%)
NWQ Managers 1,698,398 sh (+29.45%)
Joel Greenblatt 1,646,395 sh (+14.29%)
Murray Stahl 43,304 sh (+0.10%)
Jim Simons Sold Out
Pioneer Investments 384,188 sh (-0.96%)
» More
Q1 2015

BRKR Guru Trades in Q1 2015

Vanguard Health Care Fund 4,669,258 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with BRKR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 58.50
BRKR's P/E(ttm) is ranked higher than
75% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRKR: 58.50 )
BRKR' s 10-Year P/E(ttm) Range
Min: 7.15   Max: 107.17
Current: 58.5

7.15
107.17
Forward P/E 22.62
BRKR's Forward P/E is ranked higher than
81% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRKR: 22.62 )
N/A
PE(NRI) 59.20
BRKR's PE(NRI) is ranked higher than
81% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRKR: 59.20 )
BRKR' s 10-Year PE(NRI) Range
Min: 7.21   Max: 98.6
Current: 59.2

7.21
98.6
P/B 4.29
BRKR's P/B is ranked higher than
60% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.64 vs. BRKR: 4.29 )
BRKR' s 10-Year P/B Range
Min: 1.32   Max: 8.89
Current: 4.29

1.32
8.89
P/S 1.83
BRKR's P/S is ranked higher than
81% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.51 vs. BRKR: 1.83 )
BRKR' s 10-Year P/S Range
Min: 0.5   Max: 2.55
Current: 1.83

0.5
2.55
PFCF 41.57
BRKR's PFCF is ranked higher than
81% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRKR: 41.57 )
BRKR' s 10-Year PFCF Range
Min: 9.23   Max: 159.85
Current: 41.57

9.23
159.85
POCF 28.74
BRKR's POCF is ranked higher than
83% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRKR: 28.74 )
BRKR' s 10-Year POCF Range
Min: 5.78   Max: 478
Current: 28.74

5.78
478
EV-to-EBIT 29.96
BRKR's EV-to-EBIT is ranked higher than
83% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRKR: 29.96 )
BRKR' s 10-Year EV-to-EBIT Range
Min: -101.5   Max: 82
Current: 29.96

-101.5
82
PEG 118.40
BRKR's PEG is ranked higher than
89% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRKR: 118.40 )
BRKR' s 10-Year PEG Range
Min: 0.01   Max: 57.15
Current: 118.4

0.01
57.15
Shiller P/E 38.70
BRKR's Shiller P/E is ranked higher than
89% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRKR: 38.70 )
BRKR' s 10-Year Shiller P/E Range
Min: 20.11   Max: 509
Current: 38.7

20.11
509
Current Ratio 2.34
BRKR's Current Ratio is ranked higher than
68% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. BRKR: 2.34 )
BRKR' s 10-Year Current Ratio Range
Min: 1.26   Max: 4.16
Current: 2.34

1.26
4.16
Quick Ratio 1.53
BRKR's Quick Ratio is ranked higher than
60% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. BRKR: 1.53 )
BRKR' s 10-Year Quick Ratio Range
Min: 0.55   Max: 3.14
Current: 1.53

0.55
3.14
Days Inventory 200.14
BRKR's Days Inventory is ranked higher than
64% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 141.40 vs. BRKR: 200.14 )
BRKR' s 10-Year Days Inventory Range
Min: 160.3   Max: 313.08
Current: 200.14

160.3
313.08
Days Sales Outstanding 59.16
BRKR's Days Sales Outstanding is ranked higher than
81% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 84.80 vs. BRKR: 59.16 )
BRKR' s 10-Year Days Sales Outstanding Range
Min: 33.74   Max: 79.37
Current: 59.16

33.74
79.37

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 12.29
BRKR's Price/Net Current Asset Value is ranked lower than
72% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRKR: 12.29 )
BRKR' s 10-Year Price/Net Current Asset Value Range
Min: 2.67   Max: 103.75
Current: 12.29

2.67
103.75
Price/Tangible Book 5.94
BRKR's Price/Tangible Book is ranked higher than
74% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.30 vs. BRKR: 5.94 )
BRKR' s 10-Year Price/Tangible Book Range
Min: 1.35   Max: 20.45
Current: 5.94

1.35
20.45
Price/DCF (Projected) 1.95
BRKR's Price/DCF (Projected) is ranked higher than
89% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRKR: 1.95 )
BRKR' s 10-Year Price/DCF (Projected) Range
Min: 0.9   Max: 6.75
Current: 1.95

0.9
6.75
Price/Median PS Value 1.08
BRKR's Price/Median PS Value is ranked higher than
80% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. BRKR: 1.08 )
BRKR' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 7.73
Current: 1.08

0.36
7.73
Price/Graham Number 3.81
BRKR's Price/Graham Number is ranked higher than
85% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BRKR: 3.81 )
BRKR' s 10-Year Price/Graham Number Range
Min: 1.07   Max: 17.07
Current: 3.81

1.07
17.07
Earnings Yield (Greenblatt) 3.30
BRKR's Earnings Yield (Greenblatt) is ranked higher than
77% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. BRKR: 3.30 )
BRKR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.2   Max: 17.9
Current: 3.3

1.2
17.9
Forward Rate of Return (Yacktman) 1.51
BRKR's Forward Rate of Return (Yacktman) is ranked higher than
65% of the 98 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.26 vs. BRKR: 1.51 )
BRKR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -5.6   Max: 1478.7
Current: 1.51

-5.6
1478.7

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:A, ROP, GRMN, HXGBY, TRMB » details
Traded in other countries:BKD.Germany,
Bruker Corp is a designer and manufacturer of proprietary life science and materials research systems and associated products that address the rapidly evolving needs of customers in life science, pharmaceutical, biotechnological, clinical and molecular diagnostics research, and materials and chemical analysis in various industries and government applications. Its technology platforms include magnetic resonance technologies, mass spectrometry technologies, gas chromatography technologies, X-ray technologies, spark-optical emission spectroscopy, atomic force microscopy, stylus and optical metrology technology, and infrared and Raman molecular spectroscopy technologies. Company manufacture and distribute a broad range of field analytical systems for chemical, biological, radiological, nuclear and explosives, or CBRNE, detection. It also design, manufacture and market high and low temperature superconducting materials and devices based on metallic low temperature superconductors. The Company is organized into four operating segments: the Bruker BioSpin Group, the Bruker CALID Group, the Bruker MAT Group, and Bruker Energy & Supercon Technologies division. The Bruker BioSpin Group combines the Bruker Magnetic Resonance and Preclinical Imaging divisions and designs, manufactures and distributes enabling life science tools based on magnetic resonance and preclinical imaging technologies. The Bruker CALID Group combines the Bruker Life Sciences and Clinical, Bruker Chemical and Applied Markets, Bruker Detection and Bruker Optics divisions. It designs, manufactures and distributes life science mass spectrometry instruments that can be integrated and used along with other sample preparation or chromatography instruments, as well as Chemical, Biological, Radiological, Nuclear and Explosive detection products and instruments based on Raman molecular spectroscopy technologies. The Bruker MAT Group combines the Bruker AXS, Bruker Nano Surfaces, Bruker Nano Analytics and Bruker Elemental divisions and designs, manufactures and distributes spectroscopy and microscopy instruments for the analysis of composition and structure in material science and life science samples. The Bruker Energy & Supercon Technologies division develops and produces low temperature superconductor and high temperature superconductor materials for use in advanced magnet technology and energy applications as well as linear accelerators, accelerator cavities, insertion devices, other accelerator components and specialty superconducting magnets for physics and energy research and a variety of other scientific applications. Company maintains direct sales forces throughout North America, Europe, Japan, Asia Pacific and Australia. It also utilizes indirect sales channels to reach customers. It also has various international distributors, independent sales representatives, and various other representatives in parts of Asia, Latin America, and Eastern Europe. Company have broad an
» More Articles for BRKR

Headlines

Articles On GuruFocus.com
comment on BRKR Mar 23 2013 
Weekly CEO Buys Highlight: NGL, BRKR, UTHR, KTOS, GBL Dec 24 2012 
Bruker BioSciences Corp. (BRKR) CEO Frank H Laukien buys 10,000 Shares Mar 17 2011 
Bruker BioSciences Corp. (BRKR) CEO Frank H Laukien buys 1,220 Shares Mar 03 2011 
Weekly CEO Buys Highlight: Deer Consumer Products, Dynex Capital, Bruker BioSciences Corp, American Mar 27 2010 
Weekly CEO Buys Highlight: Bruker BioSciences Corp, Dynex Capital Inc, American Dairy Inc, Pioneer D Mar 21 2010 
Bruker BioSciences Corp. (BRKR) CEO Frank H Laukien buys 100,000 Shares Mar 18 2010 
Bruker BioSciences Corp. (BRKR) CEO Frank H Laukien buys 100,000 Shares Mar 15 2010 
Bruker BioSciences Corp. (BRKR) CEO Frank H Laukien buys 3,570 Shares Dec 15 2009 
Weekly CEO Buy Highlights: Bruker BioSciences Corp, Cousins Properties Inc, FIFTH STREET FINANCE, La Sep 27 2009 

More From Other Websites
Bruker Launches High-Throughput MALDI Biotypersmart System with Lifetime Laser Apr 27 2015
Bruker Introduces CE-marked IVD MALDI Sepsityper Solution for Rapid Identification of over 2,200... Apr 27 2015
Bruker Launches High-Throughput MALDI Biotypersmart System with Lifetime Laser Apr 27 2015
Bruker Introduces CE-marked IVD MALDI Sepsityper Solution for Rapid Identification of over 2,200... Apr 27 2015
Bruker Announces Date and Time of First Quarter 2015 Earnings Release and Webcast Apr 24 2015
Bruker Announces Date and Time of First Quarter 2015 Earnings Release and Webcast Apr 24 2015
Bruker Announces Innovative, High-Performance and Cost-Effective NMR Solutions for the... Apr 20 2015
Bruker Introduces Next-Generation GigaHertz NMR Technology at ENC 2015 Apr 20 2015
Bruker Introduces Next-Generation GigaHertz NMR Technology at ENC 2015 Apr 20 2015
Bruker Announces Innovative, High-Performance and Cost-Effective NMR Solutions for the... Apr 20 2015
Bruker Introduces Novel Solid-State NMR Probe with Ultra-high Spinning Frequency Apr 20 2015
Bruker Launches New High-Performance Benchtop EPR System Apr 20 2015
Bruker Introduces Novel Solid-State NMR Probe with Ultra-high Spinning Frequency Apr 20 2015
Bruker Launches New High-Performance Benchtop EPR System Apr 20 2015
Is Bruker Poised for Growth in NMR Amid Competition? - Analyst Blog Apr 14 2015
UK National Graphene Institute Selects Bruker as Official Partner Apr 06 2015
UK National Graphene Institute Selects Bruker as Official Partner Apr 06 2015
UK National Graphene Institute Selects Bruker as Official Partner Apr 06 2015
Bruker Announces FDA Clearance for Second, Expanded Claim for the MALDI Biotyper CA System Apr 03 2015
Bruker Announces FDA Clearance for Second, Expanded Claim for the MALDI Biotyper CA System Apr 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK